Glaucoma is a type of nerve blinding eye disease that is irreversible. The features of the disease and our cognitive limitations make it impossible to fully prevent development and progression. Even though many great innovations in basic science and clinical practice have been made, the clinical management and blindness rate of glaucoma have not been improved. Therefore, it is necessary that new clinical strategies be adapted that focus precisely on the management of individual glaucoma cases.
葛坚. 青光眼为什么需要精准的个体化治疗？[J]. 中华眼视光学与视觉科学杂志, 2017, 19(6): 321-323.
Jian Ge. Why Precise Personal Management is Needed in Glaucoma. Chinese Journal of Optometry Ophthalmology and Visual science, 2017, 19(6): 321-323. DOI: 10.3760/cma.j.issn.1674-845X.2017.06.001
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA, 2014, 311(18): 1901-1911. DOI: 10.1001/jama. 2014.3192.
[2]
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol, 2006, 90(3): 262-267. DOI: 10.1136/bjo.2005.081224.
[3]
The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship betweencontrolofintraocularpressureandvisualfielddeterioration. The AGIS Investigators. Am J Ophthalmol, 2000, 130(4): 429-440.
[4]
Gordon MO, Kass MA. The OcularHypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol, 1999, 117(5): 573-583.
Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology, 2005, 112(3): 376-385. DOI: 10.1016/j.ophtha.2004.10.034.
Azuara-Blanco A, Burr J, Ramsay C, et al. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. Lancet, 2016, 388(10052): 1389-1397. DOI: 10.1016/S0140-6736(16) 30956-4.
[11]
Savatovsky E, Mwanza JC, Budenz DL, et al. Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment. Ophthalmology, 2015, 122(1): 79-86. DOI: 10.1016/j.ophtha.2014.07.033.
[12]
Bhorade AM, Gordon MO, Wilson B, et al. Variability of intraocular pressure measurements in observation participants in the ocular hypertension treatment study. Ophthalmology, 2009, 116(4): 717-724. DOI: 10.1016/j.ophtha.2008.12.036.
[13]
Feuer WJ, Parrish RK, Schiffman JC, et al. The Ocular Hyper tension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center. Am J Ophthalmol, 2002, 133(1): 19-28.
[14]
De Moraes CG, Demirel S, Gardiner SK, et al. Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group. Invest Ophthalmol Vis Sci, 2012, 53(4): 1704-1709. DOI: 10.1167/iovs.11-8186.
浙公网安备 33030202001892号